B

Biolight Life Sciences Ltd
TASE:BOLT

Watchlist Manager
Biolight Life Sciences Ltd
TASE:BOLT
Watchlist
Price: 625 ILS 1.41% Market Closed
Market Cap: 27.4m ILS
Have any thoughts about
Biolight Life Sciences Ltd?
Write Note

Biolight Life Sciences Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biolight Life Sciences Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
B
Biolight Life Sciences Ltd
TASE:BOLT
Income from Continuing Operations
-â‚Ş7.3m
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
14%
Compugen Ltd
NASDAQ:CGEN
Income from Continuing Operations
$1.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Q
Quoin Pharmaceuticals Ltd
NASDAQ:QNRX
Income from Continuing Operations
-$8.3m
CAGR 3-Years
7%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
No Stocks Found

Biolight Life Sciences Ltd
Glance View

Market Cap
27.4m ILS
Industry
Life Sciences Tools & Services

BioLight Life Sciences Ltd. engages in the management, research and development, investments or sale of solutions, the purpose of which is to address a real need that exists in the field of eye diseases. Its portfolio companies are IOptima Novel Glaucoma Treatment and Micromedic Technologies Ltd. The firm provides each of the subsidiaries with ongoing support, resources and expertise in science, regulation, business development, and intellectual property. IOptima Novel Glaucoma Treatment is engaged in the development, manufacturing and distribution of novel surgical treatments for glaucoma. Micromedic Technologies Ltd focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities.

BOLT Intrinsic Value
27.24 ILS
Overvaluation 96%
Intrinsic Value
Price
B

See Also

What is Biolight Life Sciences Ltd's Income from Continuing Operations?
Income from Continuing Operations
-7.3m ILS

Based on the financial report for Jun 30, 2024, Biolight Life Sciences Ltd's Income from Continuing Operations amounts to -7.3m ILS.

What is Biolight Life Sciences Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
14%

Over the last year, the Income from Continuing Operations growth was 78%. The average annual Income from Continuing Operations growth rates for Biolight Life Sciences Ltd have been 10% over the past three years , and 14% over the past ten years .

Back to Top